NDC 85766-0229-05: Tetracaine Hydrochloride 5 mg/mL Solution
This is a package of Tetracaine Hydrochloride 5 mg/mL Solution from Sportpharm LLC, first listed with the FDA Dec 2024 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 85766-229-05 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 85766 labeler · 229 product · 05 package
- Package marketed since
- Jul 3, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 8576622905 7
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 1547771
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Ester Local Anesthetic class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 85766-0229-05 You're viewing this Main listing | 1 BOTTLE in 1 CARTON / 5 mL in 1 BOTTLE | 2026-07-03 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Tetracaine Hydrochloride 5 mg/mL 68682-0920-05 | Oceanside | 1 bottle | $4.764 | AB1 | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 82260-0920-05 | Bausch | 1 bottle | $4.939 | AB1 | Availability likely | — |
| Tetracaine Hydrochloride 5 mg/mL 70069-0596-01 | Somerset | 1 bottle | $4.939 | AB1 | Availability likely | — |
| Tetracaine Hydrochloride 5 mg/mL 70069-0597-01 | Somerset | 1 bottle | $5.043 | AB1 | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 70518-4183-00 | REMEDYREPACK | 12 bottles | — | — | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 50090-2364-01 | A-S | 4 ml | — | — | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 00187-0920-05 | Bausch | 1 bottle | — | AB1 | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 24208-0092-05 | Bausch | 1 bottle | — | AB1 | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 00065-0741-14 | Alcon | 1 bottle | — | — | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mLthis 85766-0229-05 | Sportpharm | 1 bottle | — | AB1 | FDA listed | — |
| Tetracaine Hydrochloride 5 mg/mL 85766-0230-15 | Sportpharm | 1 bottle | — | AB1 | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII R57ZHV85D4
Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
-
UNII HM4YQM8WRC
Chlorobutanol is a colorless crystalline chemical used as a preservative in medicines. It prevents bacterial and fungal growth to maintain product safety and shelf life.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 660YQ98I10
Potassium chloride is a mineral salt used in medicines as a buffer and to help maintain the proper pH balance and stability of the formulation during storage and use.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Sportpharm LLC labeler code 85766
- Acetaminophen 500 mg Tablet NDC 85766-223-01
- Pantoprazole Sodium 20 mg Tablet, Delayed Release NDC 85766-224-01
- Pantoprazole Sodium 40 mg Tablet, Delayed Release NDC 85766-225-01
- ofloxacin 3 mg/mL Solution NDC 85766-226-05
- ofloxacin 3 mg/mL Solution NDC 85766-227-10
- Naloxone Hydrochloride 4 mg/.1mL Spray, Metered NDC 85766-228-02
- Tetracaine Hydrochloride 5 mg/mL Solution NDC 85766-230-15
- Linezolid 600 mg Tablet, Film Coated NDC 85766-231-01
- Prochlorperazine Maleate 5 mg Tablet NDC 85766-232-01
- Prochlorperazine Maleate 10 mg Tablet NDC 85766-233-01
- ONDANSETRON 2 mg/mL Injection NDC 85766-234-25
- Fluticasone Propionate Diskus 50 ug Powder, Metered NDC 85766-235-50
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Tetracaine hydrochloride ophthalmic solution, 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine hydrochloride ophthalmic solution, 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. (1)
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. (2)
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Tetracaine hydrochloride ophthalmic solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Ophthalmic solution containing 0.5% tetracaine hydrochloride. (3)
⛔ Contraindications ▾
4 CONTRAINDICATIONS Tetracaine hydrochloride ophthalmic solution, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine hydrochloride ophthalmic solution, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. (4)
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. (5.1) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. (5.2) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
(5.3) For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self- administration. (5.4)
5.1Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of tetracaine hydrochloride ophthalmic solution, 0.5% may lead to damage of the corneal endothelial cells.
5.2Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.
5.3Corneal Injury Due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
5.4For Administration by Healthcare Provider Tetracaine hydrochloride ophthalmic solution, 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, 0.5% is not intended for patient self-administration [see Warnings and Precautions (5.2)] .
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [ see Warnings and Precautions (5.1)] Corneal Toxicity [ see Warnings and Precautions ( 5.2)] Corneal Injury Due to Insensitivity [ see Warnings and Precautions ( 5.3)] The following adverse reactions have been identified following use of tetracaine hydrochloride ophthalmic solution, 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. (6) To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at +1 800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.
8.2Lactation Risk Summary There are no data to assess whether tetracaine hydrochloride ophthalmic solution, 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tetracaine hydrochloride ophthalmic solution, 0.5% and any potential adverse effects on the breastfed child from tetracaine hydrochloride ophthalmic solution, 0.5%.
8.3Females and Males of Reproductive Potential No human data on the effect of tetracaine hydrochloride ophthalmic solution, 0.5% on fertility are available.
8.4Pediatric Use Safety of tetracaine hydrochloride ophthalmic solution, 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution, 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.
8.5Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution, 0.5% have been observed between elderly and younger patients.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.
🧒 Pediatric Use ▾
8.4Pediatric Use Safety of tetracaine hydrochloride ophthalmic solution, 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution, 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.
🧓 Geriatric Use ▾
8.5Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution, 0.5% have been observed between elderly and younger patients.
🆘 Overdosage ▾
10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including tetracaine hydrochloride ophthalmic solution, 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.
12.3Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of tetracaine hydrochloride ophthalmic solution, 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.
🧬 Mechanism of Action ▾
12.1Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine hydrochloride ophthalmic solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a white LDPE bottle, plugged with white LDPE nozzle and capped with white HDPE cap in the following sizes: NDC 85766-229-05, 5 mL fill in 5 mL Bottle (relabeled from NDC 70069-596-01) NDC 85766-230-15, 15 mL fill in 15 mL Bottle (relabeled from NDC 70069-597-01) After opening, this product can be used until the expiration date stamped on the bottle. Storage: Store at 15° to 25°C (59° to 77°F).
Protect from light. Do not use if solution contains crystals, cloudy, or discolored.
📋 Description ▾
11 DESCRIPTION Tetracaine hydrochloride ophthalmic solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 ● HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a white crystalline powder with a molecular weight of 300.82 Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative: chlorobutanol 0.4% Inactive ingredients: boric acid, potassium chloride, edetate disodium dihydrate, water for injection.
Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 – 6.0). Image
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries.
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of tetracaine hydrochloride ophthalmic solution, 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Topical administration of tetracaine hydrochloride ophthalmic solution, 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after instillation, with efficacy lasting 10–20 minutes. Duration of effect can be extended with repeated dosing [ see Warnings and Precautions ( 5.2) and Overdosage (10)] .
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.
📄 Recent Major Changes ▾
RECENT MAJOR CHANGES Warnings and Precautions (5.4) 2/2022
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL-5 mL 5
PRINCIPAL DISPLAY PANEL-15 mL 15
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |